These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 25962899)

  • 1. A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression.
    Leporati P; Fonte R; de Martinis L; Zambelli A; Magri F; Pavesi L; Rotondi M; Chiovato L
    BMC Cancer; 2015 May; 15():397. PubMed ID: 25962899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
    van der Lely AJ; Muller A; Janssen JA; Davis RJ; Zib KA; Scarlett JA; Lamberts SW
    J Clin Endocrinol Metab; 2001 Feb; 86(2):478-81. PubMed ID: 11157994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly.
    Ezzat S; Gaspo R; Serri O; Ur E; Chik CL
    Clin Invest Med; 2009 Dec; 32(6):E265. PubMed ID: 20003832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant.
    Drake WM; Rowles SV; Roberts ME; Fode FK; Besser GM; Monson JP; Trainer PJ
    Eur J Endocrinol; 2003 Dec; 149(6):521-7. PubMed ID: 14640992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
    Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY.
    Chanson P; Brue T; Delemer B; Caron P; Borson-Chazot F; Zouater H;
    Ann Endocrinol (Paris); 2015 Dec; 76(6):664-70. PubMed ID: 26596374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment.
    Fainstein Day P; Frohman L; Garcia Rivello H; Reubi JC; Sevlever G; Glerean M; Fernandez Gianotti T; Pietrani M; Rabadan A; Racioppi S; Bidlingmaier M
    Pituitary; 2007; 10(3):311-9. PubMed ID: 17373589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly.
    Trainer PJ; Ezzat S; D'Souza GA; Layton G; Strasburger CJ
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):549-57. PubMed ID: 19438906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Akromegaly and pharmacotherapy].
    Šiprová H; Souček M
    Vnitr Lek; 2015 Feb; 61(2):157-60. PubMed ID: 25813261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of medical therapy in the management of acromegaly.
    Vance ML; Laws ER
    Neurosurgery; 2005 May; 56(5):877-85; discussion 877-85. PubMed ID: 15854234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study.
    Sesmilo G; Resmini E; Bernabeu I; Aller J; Soto A; Mora M; Picó A; Fajardo C; Torres E; Alvarez-Escolá C; García R; Blanco C; Cámara R; Gaztambide S; Salinas I; Pozo CD; Castells I; Villabona C; Biagetti B; Webb SM
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):883-90. PubMed ID: 24612232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials.
    Jimenez C; Burman P; Abs R; Clemmons DR; Drake WM; Hutson KR; Messig M; Thorner MO; Trainer PJ; Gagel RF
    Eur J Endocrinol; 2008 Nov; 159(5):517-23. PubMed ID: 18708436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.
    Bernabeu I; Alvarez-Escolá C; Quinteiro C; Lucas T; Puig-Domingo M; Luque-Ramírez M; de Miguel-Novoa P; Fernandez-Rodriguez E; Halperin I; Loidi L; Casanueva FF; Marazuela M
    J Clin Endocrinol Metab; 2010 Jan; 95(1):222-9. PubMed ID: 19850678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.